Haojie Li

Adolph Roemer Str. 2A
Clausthal, NI 38678, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Cost-effectiveness of perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible or cisplatin-declining patients with muscle-invasive bladder cancer in the United States.

Cost-effectiveness of perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible or cisplatin-declining patients with muscle-invasive bladder cancer in the United States.

Journal: Journal of medical economics

Published: August 18, 2026

Publisher Correction: Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice.

Publisher Correction: Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice.

Journal: Oncology and therapy

Published: June 09, 2026

Upstream lithium extraction processes in lithium-ion battery recycling part 1: critical review of metallurgical process routes from an industrial point of view.

Upstream lithium extraction processes in lithium-ion battery recycling part 1: critical review of metallurgical process routes from an industrial point of view.

Journal: Waste management (New York, N.Y.)

Published: May 11, 2026

Neoadjuvant, adjuvant, and perioperative therapy comparisons in muscle-invasive bladder cancer: Clinical and methodological considerations for the interpretation of network meta-analytic findings.

Neoadjuvant, adjuvant, and perioperative therapy comparisons in muscle-invasive bladder cancer: Clinical and methodological considerations for the interpretation of network meta-analytic findings.

Journal: Urologic oncology

Published: April 11, 2026

Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice.

Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice.

Journal: Oncology and therapy

Published: January 19, 2026

Treatment Selection for Non-muscle-invasive Bladder Cancer in an Emerging Treatment Era: A Patient Preference Study.

Treatment Selection for Non-muscle-invasive Bladder Cancer in an Emerging Treatment Era: A Patient Preference Study.

Journal: Urology

Published: October 07, 2025

Cost-effectiveness of enfortumab vedotin plus pembrolizumab as a first-line treatment of locally advanced or metastatic urothelial carcinoma in the United States.

Cost-effectiveness of enfortumab vedotin plus pembrolizumab as a first-line treatment of locally advanced or metastatic urothelial carcinoma in the United States.

Journal: Journal of medical economics

Published: October 03, 2025

Treatment Patterns, Disease Recurrence, and Overall Survival in Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy: A Population-Level Claims-Based Analysis.

Treatment Patterns, Disease Recurrence, and Overall Survival in Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy: A Population-Level Claims-Based Analysis.

Journal: Clinical genitourinary cancer

Published: September 22, 2025

Real-world economic burden of disease recurrence in patients with muscle-invasive bladder cancer: A population-level claims-based analysis.

Real-world economic burden of disease recurrence in patients with muscle-invasive bladder cancer: A population-level claims-based analysis.

Journal: Journal of managed care & specialty pharmacy

Published: September 17, 2025

Evaluation of Event-Free Survival as a Surrogate Endpoint for Overall Survival in Muscle-Invasive Bladder Cancer Following Neoadjuvant Treatment: A Systematic Review and Meta-Analysis.

Evaluation of Event-Free Survival as a Surrogate Endpoint for Overall Survival in Muscle-Invasive Bladder Cancer Following Neoadjuvant Treatment: A Systematic Review and Meta-Analysis.

Journal: Oncology and therapy

Published: September 17, 2025

Real-world treatment patterns, recurrence, and overall survival of patients with muscle-invasive bladder cancer undergoing radical cystectomy in U.S. oncology practice.

Real-world treatment patterns, recurrence, and overall survival of patients with muscle-invasive bladder cancer undergoing radical cystectomy in U.S. oncology practice.

Journal: Urologic oncology

Published: September 16, 2025

Event-free survival and complete response rate as surrogate endpoints for overall survival in high-risk non-muscle-invasive bladder cancer: A meta-analysis of bacillus Calmette-Guérin-naive or -remote cases.

Event-free survival and complete response rate as surrogate endpoints for overall survival in high-risk non-muscle-invasive bladder cancer: A meta-analysis of bacillus Calmette-Guérin-naive or -remote cases.

Journal: Cancer

Published: May 30, 2025

Showing 1-12 of 33

Last Updated: 09/26/2026